Clinical Trial Search

Primary: Number of Participants With Ocular and Non-Ocular Treatment Emergent Adverse Events — 20; 25; 51; 50 Participants

Primary: Overall Horizontal Change in Alveolar Ridge Width — -1.34; -2.21 Millimeters

Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 46.1; 53.4; 0; 0 percentage of participants

Primary: Overall Survival (OS) — 12.52; 11.76 months — p=0.5625

Primary: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) — 2.35; -15.07 percent change — p=<0.001

Primary: Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female…

Primary: Change in BMI SDS (Week 0, Week 56) — -0.25; -0.02 SDS score — p=0.0022

Primary: Adverse Events in >2% Patients — 33; 7; 7; 11 participants

Primary: Percentage of Subjects With Treatment Success at Visit 4/Day 15 — 62; 71; 47; 102 Participants

Primary: Change in Quantitative Myasthenia Gravis (QMG) Scale Score — -6.4 score on a scale — p=<0.001

Primary: Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2) — -6.46; -6.38; -6.05; -7.18 millimeters of mercury (mm Hg) — p=0.2950

Primary: Number of Patients With Bacterial Vaginosis at 3 Months — 15; 16 Participants

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points…

Primary: 6 of 12 Week Overall Responder Rate — 83; 56 Participants — p=<0.02

Primary: Percentage of Participants in Part B Who Did Not Experienced a Flare — 20.2; 83.7; 79.0 percentage of participants — p=<0.001